Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trialJ. Weiß, K. Dragnev, Tibor Csőszi et al.|Annals of Oncology|2019Cited by 173
Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemiaAmanda Winters, Daniel A. Pollyea, Jeff Kaiser et al.|Blood Advances|2019Cited by 147
Trilaciclib (G1T28): A cyclin dependent kinase 4/6 inhibitor, in combination with etoposide and carboplatin (EP) for extensive stage small cell lung cancer (ES-SCLC)—Phase 1b results.Caio Max S. Rocha Lima, Taofeek K. Owonikoko, Patrick J. Roberts et al.|Journal of Clinical Oncology|2017Cited by 9